Compare Becton Dickinson and Co (BDX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Procter & Gamble Co — how do they compare? Becton Dickinson and Co trades at $156.14 (market cap $41.51B), while Procter & Gamble Co trades at $148.07 (market cap $340.16B). The key difference: Procter & Gamble Co is far larger — about 8.2× Becton Dickinson and Co's market cap, and Procter & Gamble Co pays the higher dividend (2.92%). Which is the better fit depends on your goals.
| BDX | PG | |
|---|---|---|
Market Cap | $41.51B | $340.16B |
Sector | Health | Consumer Staples |
52-Week High | $185.39 | $167.18 |
52-Week Low | $135.49 | $138.10 |
Enterprise Value | $57.97B | $365.64B |
Dividend Yield | 2.79% | 2.92% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Procter & Gamble (PG) trades at $147.58, down 0.53% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.59 beating expectations of $1.56, and robust cash flow generation. Recent developments include a new WNBA partnership and a $1.09 dividend declaration for May 2026 payment.
PG offers stable dividend income with 69 consecutive years of increases but faces premium valuation concerns amid modest growth outlook. Analyst consensus targets $161.71 with 54% buy ratings, though near-term upside may be limited by competitive pressures and economic sensitivity. The stock presents a defensive play with execution risks in maintaining margin expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
